
Non-Opioid Pain Specialist Latigo Biosciences Files for Nasdaq IPO Amid Biotech Listing Revival
The sodium channel-targeting drugmaker's public market debut signals growing investor appetite for non-addictive pain therapeutics.
VanadiumNews Research Team · 4 min · 22 Jul 2026
